Cite
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
MLA
Kanai, Masashi, et al. “A Multi-Institution Phase II Study of Gemcitabine/Cisplatin/S-1 (GCS) Combination Chemotherapy for Patients with Advanced Biliary Tract Cancer (KHBO 1002).” Cancer Chemotherapy & Pharmacology, vol. 75, no. 2, Feb. 2015, pp. 293–300. EBSCOhost, https://doi.org/10.1007/s00280-014-2648-9.
APA
Kanai, M., Hatano, E., Kobayashi, S., Fujiwara, Y., Marubashi, S., Miyamoto, A., Shiomi, H., Kubo, S., Ikuta, S., Yanagimoto, H., Terajima, H., Ikoma, H., Sakai, D., Kodama, Y., Seo, S., Morita, S., Ajiki, T., Nagano, H., & Ioka, T. (2015). A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer Chemotherapy & Pharmacology, 75(2), 293–300. https://doi.org/10.1007/s00280-014-2648-9
Chicago
Kanai, Masashi, Etsuro Hatano, Shogo Kobayashi, Yutaka Fujiwara, Shigeru Marubashi, Atsushi Miyamoto, Hisanori Shiomi, et al. 2015. “A Multi-Institution Phase II Study of Gemcitabine/Cisplatin/S-1 (GCS) Combination Chemotherapy for Patients with Advanced Biliary Tract Cancer (KHBO 1002).” Cancer Chemotherapy & Pharmacology 75 (2): 293–300. doi:10.1007/s00280-014-2648-9.